Amneal Pharmaceuticals(US:AMRX) ZACKSยท2024-11-01 15:06Company Overview - Amneal Pharmaceuticals (AMRX) is expected to report earnings for the quarter ended September 2024 on November 8, 2024, with a consensus estimate of $0.13 per share, reflecting a year-over-year decline of 31.6% [3][10] - Revenues are projected to be $693.68 million, indicating an increase of 11.9% compared to the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has been revised down by 3.33% over the last 30 days, suggesting a bearish sentiment among analysts regarding the company's earnings prospects [4][10] - The Earnings ESP (Expected Surprise Prediction) for Amneal is -2.50%, indicating that the Most Accurate Estimate is lower than the Zacks Consensus Estimate [10] Historical Performance - In the last reported quarter, Amneal exceeded the expected earnings of $0.14 per share by delivering $0.16, resulting in a positive surprise of 14.29% [11] - Over the past four quarters, Amneal has beaten consensus EPS estimates four times [12] Market Sentiment - Despite the potential for an earnings beat, the combination of a negative Earnings ESP and a Zacks Rank of 2 (Buy) complicates predictions for Amneal's performance [10] - The company does not appear to be a compelling candidate for an earnings beat, and investors are advised to consider other factors before making investment decisions [15] Industry Context - Karyopharm Therapeutics (KPTI), another player in the Zacks Medical - Drugs industry, is expected to report a loss of $0.27 per share for the same quarter, reflecting a year-over-year change of +10% [16] - Karyopharm's revenues are anticipated to be $38.15 million, up 5.9% from the previous year, but the company has a negative Zacks Rank of 4 (Sell), making predictions for an earnings beat difficult [17]